

## Tzung-Dau Wang (王宗道), MD, PhD

### Short Bio:

*Honorary President of Taiwan Hypertension Society  
Professor of Medicine, National Taiwan University Hospital & National Taiwan University College of Medicine  
Director, Division of Hospital Medicine and Cardiac Function Lab, Cardiovascular Center, Department of Internal Medicine, National Taiwan University Hospital*



Prof/Dr. Wang is currently the President of Taiwan Hypertension Society, Professor of Medicine of National Taiwan University College of Medicine, Directors of Division of Hospital Medicine and Cardiac Function Laboratory, Cardiovascular Center, Department of Internal Medicine, National Taiwan University Hospital, and the founder of Taiwan CVAI (Cardiovascular Artificial Intelligence) consortium. Prof/Dr. Wang received his medical degree from National Taiwan University Medical School (awarded the honorable membership of Phi Tau Phi Scholastic Honor Society) in 1992, his interventional cardiology fellowship training from National Taiwan University Hospital, and subsequently went on to complete a PhD program in the Graduate Institute of Clinical Medicine at National Taiwan University in 2002. In addition, he underwent advanced training at Brigham and Women's hospital and New England Deaconess hospital, Boston, USA. He had served as the director of Cardiovascular Center of National Taiwan University Hospital, Yun-Lin Branch from 2010 to 2012. Prof/Dr. Wang also earned the fellowship of European Society of Cardiology (FESC) in 2002.

Prof/Dr. Wang's research interests are extensive and currently encompass 3 fields: hypertension and blood pressure monitoring, artificial intelligence of cardiovascular imaging and physiology, and pelvic arterial intervention. He had been the global principal investigator of sacubitril/valsartan in salt-sensitive hypertension trial and local principal investigator for the GEMINI, TAO, ELIXA and RAVEL trials and co-investigator for RUTH, DISCOVERY, REACH, ACCORD and many more. He is the author of more than 250 international publications in high-ranked Journals including *Nature Genetics, Circulation, Hypertension, Eur Heart J, JAMA Network Open, J Clin Endocrinol Metab* and *Small* and has been invited to speak at numerous local and international conferences, academic meetings, and educational programs at websites including WebMD/Medscape. He is also the founder of Taiwan CVAI (Taiwan Cardiovascular Artificial Intelligence) Institute and Website.

Prof/Dr. Wang is experienced in various interventional cardiology/peripheral treatments, with more than 4,500 cases of coronary and peripheral interventions performed till now. Prof/Dr. Wang is the pioneer in developing the pelvic arterial intervention technique and pelvic CTA diagnosis for erectile dysfunction and lower urinary tract symptoms (with more than 550 cases treated till now), and has been invited to give lectures on this innovative intervention in various international intervention congresses, including TCT, EuroPCR, VIVA, EAU, ISSM/ESSM and ESC. Prof/Dr. Wang is currently serving as the regional proctor of renal denervation therapy for resistant hypertension.

Prof/Dr. Wang is the chairperson of the Task Force for Home Blood Pressure Monitoring of Taiwan Hypertension Society and Taiwan Society of Cardiology and Task Force for Renal Denervation Consensus of Taiwan Hypertension Society and Taiwan Society of Cardiology. He led the Task Force to publish the national Renal Denervation Consensus in May 2019 and Home Blood Pressure Monitoring Consensus in Nov 2020. He is the key member of the Writing Group of the 2010, 2015, and 2017 Taiwan Hypertension Guidelines. He is also the Editor-in-Chief of the *Acta Cardiologica Sinica* (SCI-indexed) and the editorial board member of *Hypertension Research, Journal of Clinical Hypertension, and Journal of Geriatric Cardiology*.

Address: Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital. No. 7, Zhong-Shan South Road, Taipei City, Taiwan, R.O.C.